{"prompt": "['SC administration in this study were based on IV-administered pertuzumab population PK', 'modelling incorporating values of SC-administered trastuzumab PK parameters. In part 1 of', 'Study BO30185, a 600 mg dose of pertuzumab SC was found to provide similar Ctrough and', 'area under the curve (AUC) as Perjeta IV delivered at a 420 mg dose. Part 2 of Study', 'BO30185 includes confirmation of the 600 mg pertuzumab SC dose when administered with', 'Herceptin SC co-mixed or as FDC in female EBC patients who have completed standard', 'adjuvant treatment. Pertuzumab SC 600 mg (co-mixed and FDC) in EBC patients was', 'confirmed to provide similar Ctrough and AUC to 420 mg Perjeta IV in healthy male volunteers', 'enrolled in study part 1. Dose proportionality through PK linearity is considered to confirm a', \"pertuzumab 1200 mg SC loading dose [Perjeta Investigator's Brochure, v17, 2018].\", 'Study BO30185 safety data are available for the healthy volunteer cohorts in part 1 and for', 'part 2 EBC cohorts receiving pertuzumab SC co-administered or co-mixed with Herceptin', 'SC. The safety results are generally consistent with prior experience with combined', 'treatment with P+H IV. Treatment in the final study cohort evaluating pertuzumab and', \"trastuzumab FDC SC in EBC is ongoing [Perjeta Investigator's Brochure, v17, 2018].\", 'Herceptin SC, pertuzumab for SC administration, and pertuzumab and trastuzumab FDC SC', 'are each formulated with 2000 U/mL human recombinant PH20 hyaluronidase (rHuPH20).', 'The excipient acts as a permeation enhancer to allow SC administration of higher drug', 'volumes. The concentration of rHuPH20 for these SC formulations was based on preclinical', 'studies in mini-pigs (an animal model selected due to its similarities with human skin', 'structure) and has been tested and found safe in clinical studies [Pivot et al. 2013, Rummel', 'et al. 2017]. Human recombinant PH20 hyaluronidase included in formulations of human', 'immunoglobulin, humanized monoclonals, and insulin has been found to induce only modest', 'immunogenicity with no associated adverse events (AEs) [Rosengren et al. 2015].', 'Consistent with these findings, anti-rHuPH20 antibodies were detected in Study BO22227 of', 'Herceptin SC, however, exploratory analyses suggest that their occurrence does not affect', \"PK or safety [Herceptin Investigator's Brochure, v18, 2017].\", 'For further details of non-clinical and clinical studies with Herceptin SC, please refer to the', \"Herceptin Investigator's Brochure. For further details of non-clinical and clinical studies with\", 'Perjeta SC and pertuzumab and trastuzumab FDC SC, please refer to the Perjeta', \"Investigator's Brochure.\", '1.3', 'STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT', '1.3.1', 'Study Rationale', 'Treatment with P+H IV has been shown to be efficacious in both early and advanced', 'metastatic HER2+ breast cancer and dual HER2 blockade with these agents has become', 'standard of care in the neoadjuvant, adjuvant and metastatic settings (see Sections 1.1 and', '1.2.4). Herceptin SC, which has been shown to have a similar safety profile and non-inferior', 'efficacy to Herceptin IV, can be administered more quickly and without requirement for IV', 'access. The relative appeal of SC administration over IV administration and the reduction in', 'time and resource use with SC administration have been reported by breast cancer patients', 'and HCPs, respectively (see Section 1.2.4).', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '33 / Protocol MO40628, Version 12']['Given the potential involvement of multiple treatment modalities including repeated IV', 'administration of multiple systemic agents, standard therapy for EBC can be a complex and', 'taxing experience for any patient. The requirements for individual drug preparation,', 'sequential infusion periods and observation periods also result in greater use of limited', 'medical resources. The development of an FDC SC formulation of pertuzumab and', 'trastuzumab provides an opportunity to build on the improvements achieved by Herceptin', 'SC by further reducing the burden associated with treatment for HER2+ breast cancer. By', \"formally assessing, from the patients' perspective, whether FDC SC administration of\", 'pertuzumab and trastuzumab is preferable to two separate, consecutive IV administrations,', 'this study will provide patient experience data to supplement the results of the ongoing', 'Roche Phase III WO20324 study comparing the PK, efficacy, and safety of these regimens.', 'This study will also document HCP reported perceptions of resource use with FDC SC', 'administration to evaluate the impact of co-formulation and SC delivery on clinical resources.', 'Study safety analyses will further characterize safety profiles of SC administration of co-', 'formulated pertuzumab and trastuzumab as well as the safety of switching from P+H IV to', 'pertuzumab and trastuzumab FDC SC and vice versa. The measurement of secondary', 'efficacy endpoints in this study will further investigate the potential effects of switching study', 'treatments on disease outcomes.', '1.3.2', 'Benefit-Risk Assessment', 'As described in Section 1.2.4, the safety and efficacy of Herceptin SC has been shown to be', 'consistent with Herceptin IV with no safety issues attributable to the route of administration', 'or to formulation with rHuPH20. Pertuzumab dosing in the FDC SC formulation has been', 'selected to provide similar PK as approved Perjeta IV dosing. No new safety issues have', 'been seen in clinical evaluation of co-infused Perjeta IV and Herceptin IV preparations (see', 'Section 1.1). Ongoing clinical evaluation of co-administered and co-formulated SC', 'preparations conducted by the Sponsor has also found no safety issues that would not be', 'expected with sequential IV administrations (see Section 1.2.4).', 'This study is being conducted in HER2+ EBC patients for whom combined treatment with', 'Perjeta IV and Herceptin is indicated. As summarized above, the benefit-risk of incorporating', \"pertuzumab and trastuzumab FDC SC into study participants' anti-HER2 regimen is based\", 'on the demonstrated non-inferiority of Herceptin SC PK profile and efficacy (as assessed by', 'pCR rate) with respect to Herceptin IV, the equivalent bioavailability of pertuzumab SC and', 'IV formulations and the consistency of safety profiles among IV, SC, and FDC SC', 'formulations.', '2.', 'OBJECTIVES AND ENDPOINTS', 'This study will evaluate patient reported preference for pertuzumab and trastuzumab FDC', 'SC in HER2+ EBC. The study will also evaluate patient reported satisfaction with', 'pertuzumab and trastuzumab FDC SC; HCP reported perception of time/resource use and', 'convenience of pertuzumab and trastuzumab FDC SC and P+H IV; patient reported health-', 'related quality of life (HRQoL); the safety of each study regimen alone and within the context', 'of the order in which they are administered; as well as efficacy in each treatment arm.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '34 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}